Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Adam Crystal Sells 5,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at approximately $2,893,575. This represents a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Adam Crystal also recently made the following trade(s):

• On Monday, November 2nd, Adam Crystal sold 5,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $22.42, for a total transaction of $112,100.00.
• On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $24.47, for a total transaction of $660,690.00.

Tango Therapeutics Stock Performance

TNGX traded up $0.65 on Friday, reaching $25.50. The company had a trading volume of 2,706,112 shares, compared to its average volume of 4,241,986. The stock has a market cap of $4.32 billion, a P/E ratio of -18.61 and a beta of 1.26. Tango Therapeutics, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $34.39. The company’s fifty day moving average is $23.53 and its 200 day moving average is $22.79.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). On average, sell-side analysts expect that Tango Therapeutics, Inc. will post -1.46 EPS for the current year.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. Allspring Global Investments Holdings LLC raised its position in Tango Therapeutics by 4.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock valued at $336,000 after purchasing an additional 534 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Tango Therapeutics by 100.9% in the 2nd quarter. Allworth Financial LP now owns 1,131 shares of the company’s stock valued at $35,000 after purchasing an additional 568 shares in the last quarter. Nykredit A S acquired a new stake in shares of Tango Therapeutics in the 2nd quarter valued at $26,000. Bleakley Financial Group LLC boosted its holdings in shares of Tango Therapeutics by 7.0% in the 3rd quarter. Bleakley Financial Group LLC now owns 13,162 shares of the company’s stock valued at $328,000 after purchasing an additional 860 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Tango Therapeutics by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after purchasing an additional 2,272 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics News Summary

These are some of the TNGX news items that stood out recently:

• Positive Sentiment: An analyst upgrade was followed by a sharp rise in Tango shares, suggesting the change in rating helped support investor sentiment. Tango Therapeutics stock price up after analyst upgrade
• Neutral Sentiment: Shares moved above their 50-day moving average despite the earnings miss, a technical signal that may indicate improving near-term momentum. TNGX moves above its 50-day moving average
• Negative Sentiment: Tango reported a quarterly loss of $0.39 per share, wider than the $0.35 loss analysts expected, underscoring continued operating losses.

Analyst Upgrades and Downgrades

TNGX has been the topic of a number of recent research reports. Zacks Research lowered Tango Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 27th. Jefferies Financial Group restated a “buy” rating and issued a $65.00 price target on shares of Tango Therapeutics in a research note on Tuesday, November 10th. HC Wainwright reduced their price target on Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. JPMorgan Chase & Co. upped their price objective on Tango Therapeutics from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 10th. Finally, Wedbush lowered their price objective on Tango Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 10th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.54.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.